Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Jit

Showing results (11-20 of 407) with videos related to

Pageof 41
Sort By:
Vaccine|July 7, 2015
Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical reviewMark Jit, Walter Mibei
International Journal of Cancer|February 16, 2018
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirusMark Jit, Marc Brisson
The Lancet. Global Health|January 27, 2019
The role of pneumococcal conjugate vaccination in reducing pneumonia mortalityMark Jit, Stefan Flasche
Annual Review of Public Health|October 23, 2023
Informing Public Health Policies with Models for Disease Burden, Impact Evaluation, and Economic EvaluationMark Jit, Alex R Cook
The Lancet. Infectious Diseases|September 25, 2021
Rapid COVID-19 vaccine rollout: immense success but challenges aheadFrank G Sandmann, Mark Jit
Health Care Management Science|August 10, 2006
A stochastic model to evaluate options for antenatal genetic screeningSteve Gallivan, Mark Jit, Martin Utley
Health Care Management Science|October 2, 2008
Restructuring routine elective services to reduce overall capacity requirements within a local health economyMartin Utley, Mark Jit, Steve Gallivan
Health Affairs (Project Hope)|February 10, 2016
Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich CountriesNiamh Herlihy, Raymond Hutubessy, Mark Jit
BMJ Global Health|January 19, 2023
Is there a role for RDTs as we live with COVID-19? An assessment of different strategiesGabrielle Bonnet, Anna Vassall, Mark Jit
Vaccine|February 23, 2011
Modelling borderline and mild dysplasia associated with HPV 6 and 11 infectionRuth Chapman, Kate Soldan, Mark Jit
Pageof 41

Showing results (11-20 of 407) with videos related to

Sort By:
Pageof 41
Vaccine|July 7, 2015
Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical reviewMark Jit, Walter Mibei
International Journal of Cancer|February 16, 2018
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirusMark Jit, Marc Brisson
The Lancet. Global Health|January 27, 2019
The role of pneumococcal conjugate vaccination in reducing pneumonia mortalityMark Jit, Stefan Flasche
Annual Review of Public Health|October 23, 2023
Informing Public Health Policies with Models for Disease Burden, Impact Evaluation, and Economic EvaluationMark Jit, Alex R Cook
The Lancet. Infectious Diseases|September 25, 2021
Rapid COVID-19 vaccine rollout: immense success but challenges aheadFrank G Sandmann, Mark Jit
Health Care Management Science|August 10, 2006
A stochastic model to evaluate options for antenatal genetic screeningSteve Gallivan, Mark Jit, Martin Utley
Health Care Management Science|October 2, 2008
Restructuring routine elective services to reduce overall capacity requirements within a local health economyMartin Utley, Mark Jit, Steve Gallivan
Health Affairs (Project Hope)|February 10, 2016
Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich CountriesNiamh Herlihy, Raymond Hutubessy, Mark Jit
BMJ Global Health|January 19, 2023
Is there a role for RDTs as we live with COVID-19? An assessment of different strategiesGabrielle Bonnet, Anna Vassall, Mark Jit
Vaccine|February 23, 2011
Modelling borderline and mild dysplasia associated with HPV 6 and 11 infectionRuth Chapman, Kate Soldan, Mark Jit
Pageof 41